149 related articles for article (PubMed ID: 15219555)
21. Daily trimethoprim-sulfamethoxazole prophylaxis rapidly induces corresponding resistance among intestinal Escherichia coli of HIV-infected adults in Kenya.
Chiller TM; Polyak CS; Brooks JT; Williamson J; Ochieng B; Shi YP; Ouma P; Greene C; Hamel M; Vulule J; Bopp C; Slutsker L; Mintz E
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):165-9. PubMed ID: 19357424
[TBL] [Abstract][Full Text] [Related]
22. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
23. Use of cotrimoxazole prophylaxis in HIV infected in patients at a referral hospital.
Khoza S; Mkudu V; Mthethwa J; Bulaya-Tembo R; Nhachi CF
Cent Afr J Med; 2010; 56(5-8):26-30. PubMed ID: 23457847
[TBL] [Abstract][Full Text] [Related]
24. Provisional WHO/UNAIDS recommendations on the use of contrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa.
;
Afr Health Sci; 2001 Aug; 1(1):30-1. PubMed ID: 12833907
[No Abstract] [Full Text] [Related]
25. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).
El-Sadr WM; Luskin-Hawk R; Yurik TM; Walker J; Abrams D; John SL; Sherer R; Crane L; Labriola A; Caras S; Pulling C; Hafner R
Clin Infect Dis; 1999 Oct; 29(4):775-83. PubMed ID: 10589887
[TBL] [Abstract][Full Text] [Related]
26. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
27. Co-trimoxazole in HIV-1 infection.
Boeree MJ; Harries AD; Zijlstra EE; Taylor TE; Molyneux ME
Lancet; 1999 Jul; 354(9175):334; author reply 335. PubMed ID: 10440330
[No Abstract] [Full Text] [Related]
28. HIV infection and AIDS.
Lloyd A
P N G Med J; 1996 Sep; 39(3):174-80. PubMed ID: 9795558
[TBL] [Abstract][Full Text] [Related]
29. Protect yourself from Pneumocystis carinii.
AIDS Alert; 1999 Jun; 14(6):suppl 1-2. PubMed ID: 11366414
[TBL] [Abstract][Full Text] [Related]
30. [Severe opportunistic infections in HIV-positive adults in sub-Saharan Africa].
Anglaret X
Med Trop (Mars); 2006 Aug; 66(4):343-5. PubMed ID: 16999042
[TBL] [Abstract][Full Text] [Related]
31. Update on opportunistic infections.
Proj Inf Perspect; 1997 Nov; (23):16-7. PubMed ID: 11365373
[TBL] [Abstract][Full Text] [Related]
32. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
33. Co-trimoxazole in HIV-1 infection.
Badri M; Maartens G; Wood R; Ehrlich R
Lancet; 1999 Jul; 354(9175):334-5. PubMed ID: 10440331
[No Abstract] [Full Text] [Related]
34. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
[TBL] [Abstract][Full Text] [Related]
35. Is it necessary to conduct trials with trimethoprim-sulphamethoxazole amongst HIV-infected individuals in Africa?
Samb B; Badiane M; Kony S; Larouzé B; Faye MA; Sow PS; Badiane S; Metro A; Costagliola D; Ndoye I; Delaporte E; Coll-Seck AM; Coulaud JP
AIDS; 1998 Mar; 12(4):447. PubMed ID: 9520181
[No Abstract] [Full Text] [Related]
36. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
[TBL] [Abstract][Full Text] [Related]
38. Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis.
Okwera A; Mafigiri DK; Guwatudde D; Whalen C; Joloba M
Afr Health Sci; 2015 Mar; 15(1):49-57. PubMed ID: 25834530
[TBL] [Abstract][Full Text] [Related]
39. Co-trimoxazole in HIV-1 infection.
Brindle R
Lancet; 1999 Jul; 354(9175):333-4; author reply 335. PubMed ID: 10440329
[No Abstract] [Full Text] [Related]
40. Co-trimoxazole in HIV-1 infection.
Hudson CP; Roach T
Lancet; 1999 Jul; 354(9175):333; author reply 335. PubMed ID: 10440328
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
